Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Jun
14
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
FDA Approval in Renal Cell Carcinoma Adjuvant Belzutifan With Pembrolizumab
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo